Common Symptoms of Fibromyalgia

Fibromyalgia  Symptoms

Workplace Accomodations

ADA accommodations FMS Day 2015

Juvenile-Onset Fibromyalgia

Juvenile FMS Day 2015 (1)

Effects of Fibromyalgia in the Workplace

Workplace Effects

Fibromyalgia Fast Facts

FMS awareness day 2015

Fibromyalgia Awareness Day 2015

cropped-safe_image.png

Today is Fibromyalgia Awareness Day.

If you know someone with Fibromyalgia, take a minute to find out one new thing about this disease.

Fibromyalgia Awareness Day 2015

safe_imageTomorrow, May 12th, is Fibromyalgia Awareness Day. All over the globe, Fibromyalgia patients and advocates will be reaching out to their local communities to help inform the world about the differences between facts and myths.

 

ua med school lib mapJoin us on the University of Arizona campus in front of the Medical School library all day tomorrow (starting at 9:30am). We’ll need lots of help answering questions about Fibromyalgia. We need volunteers for any length of time tomorrow.

Please bring a bottle of water and dress appropriately for the weather, as the weather forecast is currently 91* for tomorrow.

 

Share and Support: Saturday, March 7th at 1pm

smileDo you need to talk to other Fibromyalgia patients? Need to vent, laugh, or just BE with people who don’t ask impolite questions about your health?

Join us this Saturday, March 7th at 1pm at BJ’s Brewhouse at 5510 E Broadway Blvd (Craycroft/Broadway). We are usually seated at a large table to the LEFT of the hostess stand.

Can’t wait to see you!

Social Support: Lunch at Sweet Tomatoes (followed by CAKE)

10685393_10153186434340312_5466152158022836598_n

It’s going to be a busy weekend for SAFF! This weekend we are having lunch with the Southern Arizona POTS Group at Sweet Tomatoes (4420 N Stone) on Saturday, January 24th at 1pm. We are doing an optional white elephant exchange. If you would like to participate, please bring a silly item to exchange (under $5, does not need to be new).

 

On Sunday, January 25th, we’re going to a matinee showing of the new film Cake, starring Jennifer Aniston. We’ll be at the El Con Century Theaters (3601 E Broadway Blvd, Tucson, Arizona 85716) at 11:00 am. The showing is $6; we’ll meet in the lobby. The movie starts at 11:10am.

Famvir + Celebrex Phase II Clinical Trials

a120707_BH_091_Duffy_Carol_and_Pridgen_Skip-300x199

There’s an important clinical trial that has just wrapped up phase II that should be of interest to anyone who has Fibromyalgia. Dr. William Pridgen and Associate Professor Carol Duffy at the University of Alabama have been experimenting with the use of Famvir, an anti-viral drug that is commonly used for the treatment of Herpes Simplex, combined with Celebrex, a COX-2 inhibitor, as a method of treating Fibromyalgia.

After watching many of his patients struggle with gastrointestinal

Professor Duffy had previously isolated the herpes simplex I virus in the digestive tract of Fibromyalgia patients.

Professor Duffy had previously isolated the herpes simplex I virus in the digestive tract of Fibromyalgia patients.

issues for decades, Dr. Pridgen gave several patients Famvir on a hunch. He figured that if the GI symptoms intensified during periods of increased stress, a virus could possibly be to blame. Professor Duffy had previously isolated the herpes simplex- I virus in the GI tracts of Fibromyalgia patients.  Dr. Pridgen used Duffy’s work to guide his treatment of these FM patients. Although the patients’ symptoms improved, Dr. Pridgen felt that there must be a second drug that would provide a better result if added to the Famvir. He added Celebrex, and found that many patients responded more favorably to this combination.

Here is Dr. Pridgen’s description of the method he is using to test this hypothesis- that the combination of Famvir (famciclovir) and Celebrex (celecoxib) will result in a significant decrease in Fibromyalgia symptoms:

A total of 143 patients selected using the ACR 2010 FM criteria were enrolled at 12 sites in a 16-week, double-blind, placebo-controlled trial.  Patients were randomized (1:1) to receive a proprietary combination of celecoxib + famciclovir or placebo.  Outcome measures included a 24-hour recall pain numeric rating scale (NRS), Fibromyalgia Impact Questionnaire (FIQ-R), Patient Global Impression of Change (PGIC), and the PROMIS fatigue short form at baseline, and after 6, 12 and 16 weeks of study participation.

Here are Dr Pridgen’s results:

The primary efficacy endpoint was change in pain from baseline.  Pain reduction was evaluated using the pain NRS and the 7-day recall pain item from the FIQ-R.  Change from baseline was determined using an MMRM approach with LOCF/ BOCF imputation for missing data.  A significant decrease in pain was observed for patients on treatment vs. placebo at 16 weeks by both measures.  The absolute change on the NRS was -1.9 units vs -1.1, comparing active to placebo (p=0.031).  On the FIQ-R item, the change was -2.2 vs -0.92 (p=0.001).  Key secondary endpoints included analysis of the PGIC, where a value of “1” or “2” was considered a clinical responder.  Significantly improved PGIC response rates were noted at endpoint: 33.3% for active vs 19.2% in placebo patients (p=0.031).  Total FIQR score change at the endpoint visit was -17.54 vs -7.87 (p=0.002), while changes in the 3 domains were 14.29 vs -5.44 (p=0.004) for Function, -4.29 vs -1.89 (p=0.003) for Overall Impact, and -16.77 vs -7.90 (p=0.004) for Symptoms.  In addition, improvements in fatigue were seen at endpoint on the PROMIS fatigue (-7.62 units vs -4.15; p=0.020).

The safety profile was especially encouraging.  Despite the celecoxib component, gastrointestinal and nervous system treatment emergent adverse events were reported significantly more often in the placebo treatment group (GI:  29.0% vs 42.5%; nervous system:  17.4% vs 23.3%; active to placebo), and study completion rates favored active treatment over placebo (82.6% vs. 60.8%) (largely driven by higher placebo discontinuation rates due to adverse events and lack of efficacy).

In short, Dr. Pridgen used two different methods to track patients pain. He used a Numeric Rating Scale (NRS), which is the 0-10 scale that so many of us are so familiar with. He also used The Revised FM Impact Questionnaire (FIQR) to assist patients in reporting their pain levels. This questionnaire requires patients to respond to a variety of statements such as, “[How difficult is it to] Change sheets on bed,” on a scale that ranges from No Difficulty to Very Difficult. Both systems showed a significant decrease in symptoms following treatment with both Famvir and Celebrex.

 

In an article written by the University of Alabama, Dr Pridgen stated,

The patients who took both drugs, however, came back and said everything was better. Their fibromyalgia was gone. Their chronic fatigue was gone. Their headaches were gone. All of these things had cleared up. When the first few patients approached him, he thought it was a fluke, but as more and more and more patients said the same thing, he knew it couldn’t be a coincidence.

Here are Dr. Pridgen’s conclusions from his Phase-IIa trials:

A proprietary combination of famciclovir, which we postulate is inhibiting herpesvirus replication, and celecoxib, known to inhibit both herpesvirus replication and reactivation, was efficacious in treating multiple symptoms of FM.   Given the simultaneous improvement in many domains and the surprising tolerability of this combination of drugs, we believe this combination warrants further study as a potential new therapy for fibromyalgia patients.

 

 

Further Reading:

http://simmaronresearch.com/2014/11/drug-combo-pridgen-antiviral-fibromyalgia-trial-identified-results-available/#sthash.zb5yaKts.dpuf

 http://acrabstracts.org/abstracts/a-combination-of-celecoxib-and-famciclovir-is-efficacious-in-the-treatment-of-fibromyalgia-results-of-a-phase-iia-randomized-double-blind-placebo-controlled-study/

http://fiqrinfo.ipage.com/PRO_Newsletter_46.pdf

http://www.as.ua.edu/home/professor-surgeon-team-headed-to-third-phase-clinical-trials/